Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Date first appeared online	04/10/2018
DOI	10.1111/dom.13553
Authors	Bain S.
Journal Name	Diabetes, Obesity and Metabolism
Volume

Documents

• 44806.pdf , Book, Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC-ND).